Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm doxycycline selectively depletes aortic wall neutrophils and cytotoxic t cells

Circulation

Volumn 119, Issue 16, 2009, Pages 2209-2216

  Lindeman, Jan H N ^a   Abdul Hussien, Hazem ^a   Van Bockel, J Hajo ^a   Wolterbeek, Ron ^a   Kleemann, Robert ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Vascular and Metabolic Diseases ^*  (Netherlands)

Author keywords

Aneurysm; Immunology; Inflammation; Molecular biology; Trials

Indexed keywords

DOXYCYCLINE; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 6; INTERLEUKIN 8; ANTIINFECTIVE AGENT; CCAAT ENHANCER BINDING PROTEIN; ENZYME INHIBITOR; IL6 PROTEIN, HUMAN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR RELA;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ANEURYSM SURGERY; AORTA WALL; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG MEGADOSE; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; HUMAN; LOW DRUG DOSE; MALE; NEUTROPHIL; OPERATION DURATION; PRIORITY JOURNAL; PROTEIN CONTENT; VASCULITIS; AORTA; CONTROLLED CLINICAL TRIAL; CYTOLOGY; DRUG ANTAGONISM; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AORTA; AORTIC ANEURYSM, ABDOMINAL; CCAAT-ENHANCER-BINDING PROTEINS; DOXYCYCLINE; ENZYME INHIBITORS; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEUTROPHILS; T-LYMPHOCYTES, CYTOTOXIC; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTOR RELA; VASCULITIS;

EID: 66549112936     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.806505     Document Type: Article

References (38)

1. Baxter BT. Abdominal aortic aneurysm regression by medical treatment: possibility or pipe dream? J Vasc Surg. 2006;43:1068-1069.
2. Bergoeing MP, Thompson RW, Curci JA. Pharmacological targets in the treatment of abdominal aortic aneurysms. Expert Opin Ther Targets. 2006;10:547-559.
3. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1995;15:1145-1151.
4. Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, Ennis TL, Shapiro SD, Senior RM, Thompson RW. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000;105:1641-1649.
5. Thompson RW, Geraghty PJ, Lee JK. Abdominal aortic aneurysms: basic mechanisms and clinical implications. Curr Probl Surg. 2002;39:110-230.
6. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline inhibition of aneurysmal degeneration in an elastase- induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg. 1996;23:336-346.
7. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258-265.
8. Boyle JR, McDermott E, Crowther M, Wills AD, Bell PR, Thompson MM. Doxycycline inhibits elastin degradation and reduces metalloproteinase activity in a model of aneurysmal disease. J Vasc Surg. 1998;27:354-361.
9. Manning MW, Cassis LA, Daugherty A. Differential effects of doxy- cycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin Il-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2003;23:483-488.
10. Bartoli MA, Parodi FE, Chu J, Pagano MB, Mao D, Baxter BT, Buckley C, Ennis TL, Thompson RW. Localized administration of doxycycline suppresses aortic dilatation in an experimental mouse model of abdominal aortic aneurysm. Ann Vasc Surg. 2006;20:228-236.
11. Mosorin M, Juvonen J, Biancari F, Satta J, Surcel HM, Leinonen M, Saikku P, Juvonen T. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg. 2001;34:606-610.
12. Baxter BT, Pearce WH, Waltke EA, Littooy FN, Hallett JW Jr, Kent KC, Upchurch GR Jr, Chaikof EL, Mills JL, Fleckten B, Longo GM, Lee JK, Thompson RW. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (phase II) multicenter study. J Vasc Surg. 2002;36:1-12.
13. Curci JA, Mao D, BohnerDG, AllenBT, RubinBG, Reilly JM, Sicard GA, Thompson RW. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg. 2000;31:325-342.
14. Ding R, McGuinness CL, Burnand KG, Sullivan E, Smith A. Matrix metalloproteinases in the aneurysm wall of patients treated with low-dose doxycycline. Vascular. 2005;13:290-297.
15. Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27:1329-1342.
16. Khanna-Gupta A, Zibello T, Idone V, Sun H, Lekstrom-Himes J, Berliner N. Human neutrophil collagenase expression is C/EBP-dependent during myeloid development. Exp Hematol. 2005;33:42-52.
17. Cowland JB, Borregaard N. The individual regulation of granule protein mRNA levels during neutrophil maturation explains the heterogeneity of neutrophil granules. J Leukoc Biol. 1999;66:989-995.
18. Pagano MB, Bartoli MA, Ennis TL, Mao D, Simmons PM, Thompson RW, Pham CT. Critical role of dipeptidyl peptidase I in neutrophil recruitment during the development of experimental abdominal aortic aneurysms. Proc Natl Acad Sci U S A. 2007;104:2855-2860.
19. Eliason JL, Hannawa KK, Ailawadi G, Sinha I, Ford JW, Deogracias MP, Roelofs KJ, Woodrum DT, Ennis TL, Henke PK, Stanley JC, Thompson RW, Upchurch GR Jr. Neutrophil depletion inhibits experimental abdominal aortic aneurysm formation. Circulation. 2005;112:232-240.
20. Henderson EL, Geng YJ, Sukhova GK, Whittemore AD, Knox J, Libby P. Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes inhumanabdominal aortic aneurysms. Circulation. 1999;99:96-104.
21. 4+CD28- T-cells in patients with small abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2005;25:1347-1352.
22. Lindeman JH, Abdul-Hussien H, Schaapherder AF, Van Bockel JH, Von der Thiisen JH, Roelen DL, Kleemann R. Enhanced expression and activation of pro-inflammatory transcription factors distinguish aneurismal from atherosclerotic aorta: IL-6 and IL-8 dominated inflammatory responses prevail in the human aneurysm. Clin Sci (Lond). 2008;114:687-697.
23. Abdul-Hussien H, Soekhoe RG, Weber E, von der Thisen JH, Kleemann R, Mulder A, van Bockel JH, Hanemaaijer R, Lindeman JH. Collagen degradation in the abdominal aneurysm: a conspiracy of matrix metallo- proteinase and cysteine collagenases. Am J Pathol. 2007;170:809 -817.
24. Kloppenburg M, Brinkman BM, de Rooij-Dijk HH, Miltenburg AM, Daha MR, Breedveld FC, Dijkmans BA, Verweij C. The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. Antimicrob Agents Chemother. 1996;40:934-940.
25. Ryan ME, Usman A, Ramamurthy NS, Golub LM, Greenwald RA. Excessive matrix metalloproteinase activity in diabetes: inhibition by tetra- cycline analogues with zinc reactivity. Curr Med Chem. 2001;8:305-316.
26. Wynn RL. Latest FDA approvals for dentistry. Gen Dent. 1999;47:19-22.
27. Mukaida N, Okamoto S, Ishikawa Y, Matsushima K. Molecular mechanism of interleukin-8 gene expression. J Leukoc Biol. 1994;56:554-558.
28. Christopher MJ, Link DC. Regulation of neutrophil homeostasis. Curr Opin Hematol. 2007;14:3-8.
29. Nishizawa M, Wakabayashi-Ito N, Nagata S. Molecular cloning of cDNA and a chromosomal gene encoding GPE1-BP, a nuclear protein which binds to granulocyte colony-stimulating factor promoter element 1. FEBS Lett. 1991;282:95-97.
30. Elewski BE, Lamb BA, Sams WM Jr, Gammon WR. In vivo suppression of neutrophil chemotaxis by systemically and topically administered tetracycline. J Am Acad Dermatol. 1983;8:807-812.
31. Belsheim J, Gnarpe H, Persson S. Tetracyclines and host defense mechanisms: interference with leukocyte chemotaxis. Scand J Infect Dis. 1979;11:141-145.
32. 8+ T cells. Immunol Rev. 2003;192:131-142.
33. Schade AE, Wlodarski MW, Maciejewski JP. Pathophysiology defined by altered signal transduction pathways: the role ofJAK-STAT and PI3K signaling inleukemic large granular lymphocytes. Cell Cycle. 2006;5:2571-2574.
34. Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, Furutani A, Hoshii Y, Tanaka N, Ricci R, Ishihara T, Esato K, Hamano K, Matsuzaki M. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med. 2005;11:1330-1338.
35. Sato Y, Nishio Y, Sekine O, Kodama K, Nagai Y, Nakamura T, Maegawa H, Kashiwagi A. Increased expression of CCAAT/enhancer binding protein-beta and -delta and monocyte chemoattractant protein-1 genes in aortas from hyperinsulinaemic rats. Diabetologia. 2007;50:481-489.
36. Burger-Kentischer A, Gobel H, Kleemann R, Zernecke A, Bucala R, Leng L, Finkelmeier D, Geiger G, Schaefer HE, Schober A, Weber C, Brunner H, Ritten H, Ihling C, Bernhagen J. Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF). Atherosclerosis. 2006;184:28-38.
37. Burns JC. The riddle of Kawasaki disease. N Engl J Med. 2007;356: 659 -661.
38. Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol. 2007;119:1055-1062.